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pathogenic mutations in TP53 and CDH1 in a
patient with bilateral breast and endometrial
adenocarcinoma
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Background: Germline genetic testing for familial cancer syndromes is usually performed serially for the most likely
genetic causes. In recent years the way genetic testing carried out has changed, as next generation sequencing
now allows the simultaneous testing of multiple susceptibility genes at low costs.
Case presentation: Here, we present a female with bilateral breast cancer and endometrial adenocarcinoma.
After simultaneous sequencing of 150 genes (890 kb) associated with hereditary cancer we identified pathogenic
mutations in two high-penetrance genes, i.e. TP53 and CDH1 that would most likely not have been elucidated by
serial screening of candidate genes.
Conclusion: As the two mutated genes are located on different chromosomes and cause different cancer
syndromes these findings had a tremendous impact not only on genetic counseling of the index patient and her
family but also on subsequent surveillance strategies.
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Testing for mutations in high-penetrance cancer predis-
position genes, such as BRCA1 or BRCA2, has evolved to
an integral part of cancer care because it provides clear
information to patients and their families and established
guidelines for surveillance with proven benefit exist (www.
nccn.org). Germline genetic testing is usually performed
serially for the most likely genetic causes [1,2]. As the
genetic architecture of cancer predisposition is often
complex, genetic testing panels using next-generation
sequencing for hereditary cancers have recently been
introduced [3]. Here, we present a female with bilateral
breast cancer and endometrial adenocarcinoma, where
multiplex genetic testing revealed pathogenic mutations
in two high-penetrance genes, i.e. TP53 and CDH1. We* Correspondence: jochen.geigl@medunigraz.at
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stated.describe why traditional serial genetic testing would
most likely not have elucidated both mutations, which
had a tremendous impact on the index patient and
her family.Methods
The patient and her family received genetic counseling and
written informed consent was obtained. BRCA mutation
testing using genomic DNA extracted from peripheral
blood leukocytes (PBL) was performed. As no mutation
was identified, the index patient was included in a
study to evaluate a multiplex genetic testing panel for
individuals with cancer.
To this end a total of 150 genes corresponding to
890 kb (Additional file 1: Figure S1), which are associated
with hereditary cancer or with frequent somatic mutations
according to the COSMIC (www.sanger.ac.uk/genetics/
CGP/cosmic/) and Cancer Gene Census (www.sanger.ac.
uk/genetics/CGP/Census/) were enriched using a SeqCapLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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following the manufacturer’s instructions. Sequencing
was performed on the Roche 454FLX platform using
the Lib-L protocol (emPCR Method Manual – Lib-L LV).
For cDNA analyses we transcribed leukocyte derived
mRNA into cDNA.
Case presentation
The index patient was a 46-year old female (Figure 1; III-3)
of Afghan origin. At 38 years of age she was diagnosed
with a left sided ductal-invasive breast cancer. At 43 years
of age a FIGO Ia endometrial adenocarcinoma was
diagnosed, one year later a contralateral, i.e. right sided,
invasive breast cancer was detected. She had 4 daughters
and two sons (Figure 1; IV-1 to IV-6). One of the sons
(Figure 1; IV-1) died from a brain tumor at the age of
17 years. The other children (IV-2 to IV-6) were healthy.
One sister (Figure 1; III-1) of our index patient died at
the age of 28 years of breast cancer, diagnosed at 26 years
of age, whereas two other siblings (Figure 1; III-2, III-4)
were healthy. The mother of our index patient died at
the age of 53 years of a myocardial infarction (not shown
in the pedigree). On the maternal side there were no
cases of known malignant diseases. The family members
from the paternal side were all diagnosed and treated in
Afghanistan and we were not able to retrieve written
documentation. According to the relatives, the father
(Figure 1; II-1) died with 63 years of age of gastric cancer.
His uncle (Figure 1; I-2) was also diagnosed with gastric
cancer at “high age” (>80 years), the son (Figure 1; II-2) of
this uncle died of an unknown malignant disease and his
two grand-daughters (Figure 1; III-5, III-6) both died at
young ages of breast cancer.
The history allowed the differential diagnosis of three
autosomal dominantly inherited cancer predispositionFigure 1 Pedigree of a family with mutations in both TP53 and CDH1
marked in different colours. Age in years [y] at diagnosis or current age is isyndromes. First, the familial breast-ovarian cancer either
due to heterozygous germline mutations in BRCA1
(OMIM #604370) or BRCA2 (OMIM #612555), because
the index patient and her sister had early-age-onset
(≤50 years) breast cancer and the index patient bilateral
disease [4]. Second, Li-Fraumeni syndrome (LFS, OMIM #1
51623) caused by germline mutations of TP53, which
presents with a variety of tumor types, most notably
sarcomas, breast cancer, adrenal cortical carcinoma, and
brain tumors [5]. Breast cancer is the most common
tumor in women with LFS [6]. TP53 genetic testing could
have been considered according to the Chompret criteria
[7,8] because both the index patient and one first-degree
relative, i.e. her son, had cancers from the LFS tumor
spectrum (breast, brain) before 46 years of age. Third,
hereditary diffuse gastric cancer (HDGC, OMIM #137215)
characterized by diffuse-type gastric cancer and an elevated
risk of lobular breast cancer, which is caused by germline
mutations of CDH1 coding for E-cadherin [9]. However,
the current criteria for CDH1 genetic testing [10] require
histopathological confirmation of diffuse gastric cancer
in at least one family member, which we did not have,
and both gastric cancer cases were not diagnosed below
the age of 50 years.
As families who have a predominance of premenopausal
breast cancer are more likely to have mutations in BRCA1
or BRCA2 than in TP53 [11], we started our diagnostic
work-up with Sanger sequencing and MLPA (Multiplex
Ligation-dependent Probe Amplification) of the two
breast cancer genes. However, this did not reveal disease-
associated mutations.
We next offered the index patient participation in a
study with the aim to evaluate a multiplex genetic testing
panel for individuals with cancer. This study was approved
by the Ethics Committee of the Medical University ofshowing inheritance of different types of tumors. Cancer types are
ndicated below the symbols. Blue arrow indicates the index patient.
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written informed consent, we performed targeted rese-
quencing of 150 genes (890 kb) associated with hereditary
cancer or with frequent somatic mutations according to
the COSMIC (www.sanger.ac.uk/genetics/CGP/cosmic/)
and Cancer Gene Census (www.sanger.ac.uk/genetics/
CGP/Census/) databases. SNV calling identified a total
of 446 variants. These variants were filtered first for the
non-synonymous, splice acceptor-site and donor-site and
insertions/deletions mutation and then against available
public databases (dbSNP132, 1000 Genome variants data-
bases). After this variant prioritization we identified
heterozygous germline mutations in two high-penetrance
genes, i.e. TP53 (c.673-1 G >A) and CDH1 (c.892 G > A,
p.A298T), and one mutation in NUP214 (c.2160A > C,
p.L720F) which we confirmed by Sanger sequencing
(Additional file 2: Table S1). The CDH1 mutation was
previously reported in a family with three affected
members with diffuse gastric cancer. The mutation
dramatically decreases the ability of E-cadherin to me-
diate cell-cell adhesion and to suppress cell invasion
and is therefore listed as causative in HGMD [12,13].
The TP53 mutation had also been previously observed in
a LFS family and analysis of the cDNA had demonstrated
that this mutation resulted in a variant transcript [14].
We had only leukocyte derived mRNAs available toFigure 2 H& E- and immunostaining of p53 and E-cadherin proteins i
carcinoma showing an invasive carcinoma, grade 2, with focal lobular featu
lobular component. C, D) Immunostaining for E-cadherin. Positive cells (bro
within the component with lobular features. E, F) Immunostaining for p53confirm this; however, no splice variants were detected in
the respective cDNAs. Similar observations with leukocyte
derived mRNAs were previously reported for other TP53
splice site mutations [15] and indicate most likely that
the resulting transcripts were unstable and subsequently
degraded. As we could not repeat these experiments
with an immortalized cell line we carefully analyzed
available tumor material from our index patient with
immunohistochemistry as outlined below. The NUP214
mutation was not previously reported. To explore the
significance of these mutations further, we analyzed
them using various prediction programs including
SIFT, PolyPhen, and LRT. As expected for the two pre-
viously reported pathogenic mutations in CDH1 and
TP53 these prediction programs indicated structurally
damaging effects. In contrast, these programs suggested for
the NUP214 mutation a non-pathogenic effect. Somatic
NUP214 mutations were mainly reported in cervix and
endometrium carcinoma (http://cancer.sanger.ac.uk/cosmic/
gene/analysis?ln=NUP214#dist), whereas germline NUP214
were to best of our knowledge never reported. Altogether
this suggests that the NUP214 mutation does not contribute
to the tumor spectrum in our patient.
Histology of the left-sided breast carcinoma was not
available, since surgery had been performed in Pakistan.
All sections of the right-sided breast carcinoma weren different tumor sections. A) H&E staining of the right-sided breast
res. B) H& E staining of the right-sided breast carcinoma showing the
wnish) are present at the membrane but in a clearly lower portion
was negative for both, the invasive and the intraductal carcinoma.
Figure 3 Different organs are affected with cancer in one
family. Left: tumors observed in males; right: tumors in females; the
most likely causative gene is indicated for each tumor.
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of no special type, grade 2, with focal lobular features
(mixed invasive carcinoma) and an associated minor
grade 2 intraductal component (Figure 2A). The lobular
component was composed of small cells with mono-
morphic nuclei, arranged in single cell files (Figure 2B).
Immunohistochemistry showed membrane staining forFigure 4 Possible segregation patterns of the two mutated genes tha
paternal chromosomes.E-cadherin, which was less intense within the component
with lobular features (Figure 2C-D). TP53 expression was
absent in both the invasive and the intraductal carcinoma
(Figure 2E-F), indicating that the spliced mutant protein
is not expressed. The endometrial adenocarcinoma was
of endometrioid type with secretory changes and showed
immunoreactivity for E-cadherin, but a flat negative
immunoreactive pattern for TP53.
Conclusion
Our case represents a diagnostic challenge: In the family
several different organs are involved, i.e. breast, stomach,
uterus, and brain (Figure 3). As several family members
were diagnosed and treated abroad, written documentation
was incomplete. With traditional serial genetic diagnostics,
TP53 testing would have been the most likely next step
after BRCA1/BRCA2 sequencing. Although an uncommon
manifestation of LFS, gastric cancer has been suggested to
be a component of the LFS tumor spectrum [16] so
that all tumors in this family could have been attributed
to the TP53 germline mutation without apparent need
for further sequencing of other genes. However, the correct
identification of germline mutations is important because
LFS and HDGC require intensive and different clinical
management.
The lifetime risk of developing cancer is estimated at
be as high as 73% for male and 93% for female germline
TP53mutation carriers [17]. While in the past LFS screen-
ing programs often lacked effectiveness a recent novel
surveillance protocol using non-invasive biochemical and
imaging modalities enabled the presymptomatic detection
of malignancies in TP53 mutation carriers and prolongedt are located on different chromosomes. red: maternal; blue:
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management options and may change attitudes towards
genetic TP53 screening.
Carriers of CDH1 germline mutations have a cumulative
gastric cancer risk, before age 75, of 40–67% for men and
63–83% for women and a risk for lobular breast cancer of
39–52% [19]. Total prophylactic gastrectomy is the only
reliable intervention for carriers of pathogenic mutations
[9] and was discussed with our patient, illustrating how
multiplex genetic testing can change clinical management.
Furthermore, this situation presents a challenge for
genetic counseling as the two mutated genes are located
on different chromosomes, i.e. CDH1 on chromosome
16q22.1 and TP53 on 17p13.1. Each mutation is inherited
with a 50% chance. There is only a 25% probability that a
child will inherit no mutation, a 50% chance to inherit one
of the two mutated genes and a 25% chance to inherit
both (Figure 4). It is very likely that the son, who died
at 17 years of age (IV-1 in Figure 1) had at least inherited
the mutated TP53, as LFS-related brain tumors can occur
in either childhood or adulthood with a median age of
onset of 16 years [6]. The 28 and 25 year old daughters
(IV-2, IV-3) live in Afghanistan and were not available for
genetic testing. We identified the CDH1 but not the TP53
mutation in the second son (IV-4), whereas no mutation
was found in the two younger daughters (IV-5, IV-6).
In summary, we demonstrate a case, where multiplex
genetic testing enabled us to establish a diagnosis, which
would likely have been missed with serial testing.
However, the increased risk for detection of variants of
unknown significance represents a concern of multiplex
genetic panels [3]. An example is the NUP214 mutation,
which we observed in the index patient and which very
likely did not increase tumor susceptibility. To address this
issue we now designed gene panels that only include high
penetrance gene with clear implications to hereditary
tumor syndromes. The growing awareness about the
importance of identifying mutation carriers was recently
reflected in recommendations released by the American
College of Medical Genetics and Genomics [20]. These
guidelines state that anyone whose genome is sequenced
for any medical reason should automatically learn -without
further consent- about mutations in the cancer-predispos-
ition genes for which risk reducing or live saving measures
exist. This proposed shift in handling genetic data and
the complexity of hereditary multigene cancer panels
as illustrated in this report represent novel challenges
for cancer genetics professionals.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompanying
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review by the Editor of this journal.Additional files
Additional file 1: Figure S1. Electropherogramm and IGV alignment
showing mutations in TP53 and CDH1.
Additional file 2: Table S1. List of genes that were enriched for
sequencing.
Competing interests
The authors indicated no potential conflicts of interest.
Authors’ contributions
EH: Project planning and experimental design. Sequencing, next-generation
sequencing and data analysis and drafted the manuscript. Manuscript writing,
SL: Review of histology IL: Review of clinical data. GP: Review of clinical data. PU:
Sequencing, next-generation sequencing and data analysis. SJ: Review of
histology. CH: Review of clinical data. EP: Review of clinical data. MRS: Project
planning and experimental design, Manuscript writing. JBG: Project planning
and experimental designs Review of clinical data, Manuscript writing. All authors
read and approved the final manuscript.
Acknowledgements
Funding was provided by the Förderung durch die Steiermärkische
Landesregierung GZ: A3-16.M-94/2009-14.
Author details
1Institute of Human Genetics, Medical University of Graz, Harrachgasse 21/8,
A-8010 Graz, Austria. 2Department of Pathology, General Hospital Graz West,
Goestingerstrasse 22, A-8020 Graz, Austria. 3Department of Obstetrics and
Gynecology, Medical University of Graz, Auenbruggerplatz 14, A-8036 Graz,
Austria. 4Institute of Pathology, Medical University of Graz, Auenbruggerplatz
25, A-8036 Graz, Austria. 5Division of Gastroenterology and Hepatology,
Medical University of Graz, Auenbruggerplatz 15, A-8036 Graz, Austria.
Received: 12 September 2013 Accepted: 18 December 2013
Published: 29 December 2013
References
1. Weitzel JN, Blazer KR, Macdonald DJ, Culver JO, Offit K: Genetics, genomics,
and cancer risk assessment: state of the art and future directions in the
Era of personalized medicine. CA Cancer J Clin 2011, 61:327–359.
2. Speicher MR, Geigl JB, Tomlinson IP: Effect of genome-wide association
studies, direct-to-consumer genetic testing, and high-speed sequencing
technologies on predictive genetic counselling for cancer risk. Lancet
Oncol 2010, 11:890–898.
3. Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME: Multiplex genetic
testing for cancer susceptibility: out on the high wire without a net?
J Clin Oncol 2013, 31:1267–1270.
4. Shannon KM, Chittenden A: Genetic testing by cancer site: breast. Cancer J
2012, 18:310–319.
5. Mai PL, Malkin D, Garber JE, Schiffman JD, Weitzel JN, Strong LC, Wyss O,
Locke L, Means V, Achatz MI, Hainaut P, Frebourg T, Evans DG, Bleiker E,
Patenaude A, Schneider K, Wilfond B, Peters JA, Hwang PM, Ford J, Tabori U,
Ognjanovic S, Dennis PA, Wentzensen IM, Greene MH, Fraumeni JF Jr,
Savage SA: Li-Fraumeni syndrome: report of a clinical research workshop
and creation of a research consortium. Cancer Gene 2012, 205:479–487.
6. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA:
Li-Fraumeni and related syndromes: correlation between tumor type,
family structure, and TP53 genotype. Cancer Res 2003, 63:6643–6650.
7. Chompret A, Abel A, Stoppa-Lyonnet D, Brugieres L, Pages S, Feunteun J,
Bonaiti-Pellie C: Sensitivity and predictive value of criteria for p53
germline mutation screening. J Med Genet 2001, 38:43–47.
8. Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E,
Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaiti-Pellie C,
Stoppa-Lyonnet D, Frebourg T: 2009 version of the Chompret criteria for
Li Fraumeni syndrome. J Clin Oncol 2009, 27:e108–109. author reply e110.
9. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F: E-cadherin
alterations in hereditary disorders with emphasis on hereditary diffuse
gastric cancer. Prog Mol Biol Transl Sci 2013, 116:337–359.
10. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V,
Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C:
Heitzer et al. BMC Medical Genetics 2013, 14:129 Page 6 of 6
http://www.biomedcentral.com/1471-2350/14/129International gastric cancer linkage C: hereditary diffuse gastric cancer:
updated consensus guidelines for clinical management and directions
for future research. J Med Genet 2010, 47:436–444.
11. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC,
Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC: Spectrum
of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk
of breast cancer. JAMA 2006, 295:1379–1388.
12. Brooks-Wilson AR, Kaurah P, Suriano G, Leach S, Senz J, Grehan N,
Butterfield YS, Jeyes J, Schinas J, Bacani J, Kelsey M, Ferreira P, MacGillivray B,
MacLeod P, Micek M, Ford J, Foulkes W, Australie K, Greenberg C, LaPointe M,
Gilpin C, Nikkel S, Gilchrist D, Hughes R, Jackson CE, Monaghan KG, Oliveira MJ,
Seruca R, Gallinger S, Caldas C, et al: Germline E-cadherin mutations in
hereditary diffuse gastric cancer: assessment of 42 new families and review
of genetic screening criteria. J Med Genet 2004, 41:508–517.
13. Mateus AR, Simoes-Correia J, Figueiredo J, Heindl S, Alves CC, Suriano G,
Luber B, Seruca R: E-cadherin mutations and cell motility: a
genotype-phenotype correlation. Exp Cell Res 2009, 315:1393–1402.
14. Bougeard G, Limacher JM, Martin C, Charbonnier F, Killian A, Delattre O,
Longy M, Jonveaux P, Fricker JP, Stoppa-Lyonnet D, Flaman JM, Frebourg T:
Detection of 11 germline inactivating TP53 mutations and absence of
TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or
Li-Fraumeni-like syndrome. J Med Genet 2001, 38:253–257.
15. Verselis SJ, Rheinwald JG, Fraumeni JF Jr, Li FP: Novel p53 splice site
mutations in three families with Li-Fraumeni syndrome. Oncogene 2000,
19:4230–4235.
16. Masciari S, Dewanwala A, Stoffel EM, Lauwers GY, Zheng H, Achatz MI,
Riegert-Johnson D, Foretova L, Silva EM, Digianni L, Verselis SJ, Schneider K,
Li FP, Fraumeni J, Garber JE, Syngal S: Gastric cancer in individuals with
Li-Fraumeni syndrome. Genet Med 2011, 13:651–657.
17. Chompret A, Brugieres L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A,
Hua D, Ligot L, Dondon MG, Bressac-de Paillerets B, Frebourg T, Lemerle J,
Bonaiti-Pellie C, Feunteun J: P53 germline mutations in childhood cancers
and cancer risk for carrier individuals. Br J Cancer 2000, 82:1932–1937.
18. Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A,
Finlay J, Malkin D: Biochemical and imaging surveillance in germline TP53
mutation carriers with Li-Fraumeni syndrome: a prospective observational
study. Lancet Oncol 2011, 12:559–567.
19. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G,
Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S,
Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon
W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers
G, Pizzuti A, Vaccaro C, Redal MA, et al: Founder and recurrent CDH1
mutations in families with hereditary diffuse gastric cancer. JAMA 2007,
297:2360–2372.
20. Couzin-Frankel J: Genome sequencing. Return of unexpected DNA results
urged. Science 2013, 339:1507–1508.
doi:10.1186/1471-2350-14-129
Cite this article as: Heitzer et al.: Multiplex genetic cancer testing
identifies pathogenic mutations in TP53 and CDH1 in a patient with
bilateral breast and endometrial adenocarcinoma. BMC Medical Genetics
2013 14:129.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
